Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
Jerry H. Houl(The University of Texas MD Anderson Cancer Center), John A. Tainer(The University of Texas MD Anderson Cancer Center), Roderick A. Stegeman(Washington University in St. Louis), Darin E. Jones(University of Arkansas at Little Rock), Daniel J. Laverty(Massachusetts Department of Public Health), In‐Kwon Kim(University of Cincinnati), Sarita Namjoshi(The University of Texas MD Anderson Cancer Center), L.S. Warden(The University of Texas MD Anderson Cancer Center), Yasin Pourfarjam(University of Cincinnati), Tom Ellenberger(Harvard University), Davide Moiani(The University of Texas MD Anderson Cancer Center), Zachary D. Nagel(Harvard University), Mien‐Chie Hung(Precision Therapeutics (United States)), Naga Babu Chinnam(The University of Texas MD Anderson Cancer Center), Zamal Ahmed(The University of Texas MD Anderson Cancer Center), Zu Ye(Chinese Academy of Sciences), L.P.F. Balapiti-Modarage(University of Arkansas at Little Rock), Mei‐Kuang Chen(The University of Texas MD Anderson Cancer Center), Chris A. Brosey(The University of Texas MD Anderson Cancer Center), Brian L. Walker(University of Arkansas at Little Rock), Albino Bacolla(The University of Texas MD Anderson Cancer Center)
Cited by 135
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
|Nature Communications|2018|427
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
|Journal of Clinical Investigation|2019|380
Microbial metalloproteomes are largely uncharacterized
|Nature|2010|363